TScan Therapeutics (TCRX) Retained Earnings (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Retained Earnings of -$533.5 million for Q1 2026, down 13338100.0% year-over-year from N/an in Q1 2025, and down 5.68% quarter-over-quarter from -$504.9 million in Q4 2025.
TScan Therapeutics (TCRX) Retained Earnings (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Retained Earnings for 7 consecutive years, with -$533.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 13338100.0% year-over-year to -$533.5 million; the TTM figure through Mar 2026 stood at -$533.5 million (down 13338100.0% YoY), while the FY2025 annual figure was -$504.9 million, down 34.6% from the prior year.
- Retained Earnings eased to -$533.5 million in Q1 2026 per TCRX's latest filing, from -$504.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$4000.0 in Q1 2025 and bottomed at -$533.5 million in Q1 2026.
- Historically, Retained Earnings has averaged -$274.1 million across 5 years, with a median of -$247.6 million in 2023.
- Annual changes were most pronounced in 2025 — Retained Earnings soared 100.0% — and 2026, when it slumped 13338100.0%.
- TScan Therapeutics' Retained Earnings stood at -$158.4 million in 2022, then tumbled by 56.33% to -$247.6 million in 2023, then plunged by 51.49% to -$375.1 million in 2024, then slumped by 34.6% to -$504.9 million in 2025, then declined by 5.68% to -$533.5 million in 2026.
- Business Quant data shows TCRX's Retained Earnings at -$533.5 million in Q1 2026, -$504.9 million in Q4 2025, and -$481.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -563.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -563.90 Mn |
| Mar 31, 2026 | -533.53 Mn |
| Dec 31, 2025 | -504.86 Mn |
| Sep 30, 2025 | -481.90 Mn |
| Jun 30, 2025 | -446.20 Mn |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | -375.10 Mn |
| Sep 30, 2024 | -339.29 Mn |
| Jun 30, 2024 | -309.40 Mn |
| Mar 31, 2024 | -277.70 Mn |
| Dec 31, 2023 | -247.60 Mn |
| Sep 30, 2023 | -228.00 Mn |
| Jun 30, 2023 | -204.99 Mn |
| Mar 31, 2023 | -180.90 Mn |
| Dec 31, 2022 | -158.38 Mn |
| Sep 30, 2022 | -139.66 Mn |
| Jun 30, 2022 | -123.41 Mn |
| Mar 31, 2022 | -108.31 Mn |
| Dec 31, 2021 | -92.16 Mn |
| Sep 30, 2021 | -77.96 Mn |